Type 2 Diabetes

Current study in Lancet showed that patients reduced their A1c levels by 1.55%.

Therapy said superior to a basal/bolus insulin regimen at lowering HbA1c with less hypoglycemia and weight gain.

Let’s start off with what is in the pipeline.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

Adults with type 2 diabetes and microvascular complications have an increased risk for severe periodontitis compared with those without microvascular complications.

Survey estimates that diabetes accounts for many more deaths in the United States than are being reported on death certificates — and that diabetes is actually the third leading cause of death.

Phase-3 study to evaluate efficacy and safety of ertugliflozin monotherapy.

Study shows significant improvement in diabetes control with a 1 point drop in A1c with less hypoglycemia.

FDA label update will increase drug use in persons with historical contraindications or precautions.

Using fibrates to treat hypertriglyceridemia has not shown significant benefit in cardiovascular mortality in previous studies.